m+Medelevator.RU
← Поиск публикаций
ACS omega · 2024

Deep Multitask Learning-Driven Discovery of New Compounds Targeting Leishmania infantum.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Santos Eder Soares de Almeida, Lemos Jade Milhomem, Dos Santos Carvalho Alexandra Maria, Mendonça de Melo Felipe da Silva, Pereira Eufrasia de Sousa, Moreira-Filho José Teófilo, Braga Rodolpho de Campos, Muratov Eugene N, Grellier Philippe, Charneau Sébastien, Bastos Izabela Marques Dourado, Neves Bruno Junior

Аннотация

Visceral leishmaniasis caused by Leishmania infantum is a severe and often fatal disease prevalent in low- and middle-income countries. Existing treatments are hampered by toxicity, high costs, and the emergence of drug resistance, highlighting the urgent need for novel therapeutics. In this context, we developed an explainable multitask learning (MTL) pipeline to predict the antileishmanial activity of compounds against three Leishmania species, with a primary focus on L. infantum. Then, we screened ∼1.3 million compounds from the ChemBridge database by using these models. This approach identified 20 putative hits, with nine compounds demonstrating significant in vitro antileishmanial activity against L. infantum. Three compounds exhibited notable potencies (IC50 of 1.05-15.6 μM) and moderate cytotoxicities (CC50 of 32.4 to >175 μM), positioning them as promising candidates for further hit-to-lead optimization. Our study underscores the effectiveness of multitask learning models in virtual screening, enabling the discovery of potent and selective antileishmanial compounds targeting L. infantum. Incorporating explainable techniques offers critical insights into the structural determinants of biological activity, aiding in the rational design and optimization of new therapeutics. These findings advocate for the potential of multitask learning methodologies to enhance hit rates in drug discovery for neglected tropical diseases.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты